Effects of General Practice Pharmacists on
. So far, evidence on the effectiveness in terms of clinical outcomes such as morbidity or mortality is lacking. Hence, the aim of this study was to evaluate the effect of general practice pharmacists on medication-related hospitalisations.
Design: A multicentre, pragmatic, controlled intervention study with pre-post comparison (2013 versus June 2014-May 2015) comparing general practice pharmacist-led care (intervention) with two current models of pharmaceutical care (usual care and usual care plus). Setting: Twenty-five general practices in the Netherlands Participants: Patients at high risk of medication problems, defined as being aged 65 years or older and using five or more chronic medications Intervention and controls: For the intervention group, ten specially trained pharmacists were employed in general practices to take integral responsibility for the pharmaceutical care. They provided a broad range of services both on patient level (e.g., clinical medication review) and practice level (e.g., quality improvement projects). In the control groups, pharmaceutical care was provided 'as usual' by general practitioners collaborating with a community pharmacist and 'as usual plus' where community pharmacists had an additional training in performing medication reviews. Assessment of medication-related hospitalisations: multistep and case-by-case by an expert panel of all acute hospital admissions, based on a modified version of the algorithm by Kramer et al 3 . Analysis: a Poisson mixed model with adjusted rate ratios The preliminary results showed that overall, 822 possible medication-related hospitalisations were identified among 11,281 high-risk patients during the intervention period. After adjustment for clustering and adjustment for potential confounders, the mean rates of medication-related hospitalisations were lower in the intervention and usual care plus group than in the usual care group. As a result, the adjusted rate ratio of medication-related hospitalisations was significantly lower in the intervention group compared to usual care. No difference was found between the intervention group and the usual care plus group.
General practice pharmacists play a vital role in improving medication safety by reducing medication-related hospitalisations compared with usual care. Interestingly, outcomes in intervention and usual care plus practices did not differ. This is probably related to the fact that the usual care plus practices were already highly integrated care settings. Since the researchers chose not to randomise, the comparison is at risk of bias, even though the results were corrected for baseline differences. The hospitalisations were also possibly medication-related, including various levels of certainty about the causality. To assess definite causality (if possible), data including interviews with involved doctors, pharmacists and patients would have been necessary. To conclude, high-risk patients will benefit most from integrated pharmaceutical care and further implementation of general practice pharmacists should be promoted. Atrial fibrillation (AF), the most common heart arrhythmia in clinical practice, presents significant morbidity and mortality to patients. The prevalence and incidence of AF continues to rise, potentially reaching epidemic rates in the next 10-20 years. Therefore, early and accurate detection is vital to ensuring patients' risks are minimised. The primary aim of this descriptive study was to assess the role pharmacists could have in providing this early detection and subsequent referral to care using the Alivecor Kardia single-lead ECG device in a non-clinical setting. Assessing differences in CHA 2 DS 2 -VASc associated risk factors between groupings of patients was a secondary focus.
This study took place during three consecutive AF awareness weeks in London, UK. Patients were enrolled on a voluntary basis and free pulse checks and health screenings were offered to all potential patients ≥18 years of age, regardless of past medical history, after obtaining written consent. Pharmacists and nurses utilised the Alivecor Kardia single-lead ECG device to place patients into "normal", "unclassified", and "possible AF" groupings. Information needed to assess CHA2DS2-VASc risk factors was obtained from the patient reported health screenings. For any irregularity detected, individualised counselling and an immediate 12-lead ECG work-up or referral to a local general practitioner was provided. St. Bartholomew's Health Clinical Effectiveness Unit granted ethical approval for this study.
In total, 1,298 patients were enrolled, of which 154 were excluded due to incomplete data. The 1,144 remaining patients held a mean age of 54.99 years, median age of 57 years, and range of 18-101 years old. In this population, 371 (32.4%) participants were ≥65 years old with 505 (44.1%) being female. Of these 1,144 profiles, 37 patients (3.2%) were identified as potentially or knowingly having AF at the time of screening, 25 (67.6%) of which were ≥65 years old. 62 patients (5.4%) showed a non-AF irregularity, with the remaining 1,045 patients (91.3%) having a "normal" rhythm upon screening. The 37 patients with possible or confirmed AF had a mean CHA 2 DS 2 -VASc score of 2.30, compared to 1.36 in the "normal" rhythm grouping. The 25 patients ≥65 years old in the AF grouping had an average CHA 2 DS 2 -VASc score of 3. The most commonly reported risk factors for the overall patient population were hypertension, peripheral artery disease, and diabetes, which were reported in 29.5%, 15.0%, and 13.1% of the population, respectively.
Strengths of this study include its multi-site, non-invasive and easily replicable design, as well as its open inclusion criteria. The reliance on patient-reported information for certain data constitutes a potential weakness. Despite this, pharmacist-led ECG screenings resulted in 99 patients (8.7%) being identified and referred to follow-up care, 18 (1.6%) of which were suspected to have previously unknown AF. Based on these results, there is a potential role for pharmacists in the detection and referral to care for AF in non-clinical settings. Differences between CHA 2 DS 2 -VASc associated risk factors based on age and heart rhythm grouping were also shown, and could be further studied to target specific patient populations for future screening efforts. Keywords Atrial fibrillation, Kardia, Pharmacist, Screening
